MCL Literature Feed

Optical genomic mapping (OGM) identifies rare CCND1 rearrangements, securing an MCL diagnosis in atypical CD5-negative, non-nodal cases that mimic other indolent B-cell lymphomas.

A novel BRAF N581S mutation was identified in mantle cell lymphoma, expanding the known genomic landscape and suggesting a potential new therapeutic target for this rare patient subset.

Upregulation of the mTOR pathway drives acquired resistance to PRMT5 inhibitors in preclinical MCL models; combining with an mTOR inhibitor like temsirolimus overcomes this resistance and improves survival.

This pathology workshop report clarifies the differential diagnosis of aggressive B-cell lymphomas, including pleomorphic MCL, by applying updated WHO-HAEM5 and ICC 2022 classifications for improved diagnostic accuracy.

This review synthesizes MCL's genomic heterogeneity with the evolving therapeutic landscape, focusing on novel agents like BTKi and CAR-T and strategies for overcoming resistance in relapsed/refractory disease.

This review identifies the lncRNA LINK-A as an upregulated oncogene in MCL, presenting it as a potential biomarker and therapeutic target involved in oncogenic pathways and therapy resistance.

This review identifies the lncRNA ROR1-AS1 as a pro-oncogenic factor in mantle cell lymphoma, suggesting it may serve as a novel biomarker or therapeutic target.

This Mendelian randomization study suggests potential causal links between socioeconomic factors and lymphoma development, which may help define modifiable risk factors relevant to MCL etiology.

This case report describes a rare transformation of CD5-negative MCL into an EBV-positive pleomorphic variant, highlighting a potential role for EBV in aggressive disease progression and diagnosis.

A novel 7-gene signature linked to ferroptosis predicts overall survival in MCL, identifying high-risk patients and suggesting potential new therapeutic targets like the MEK inhibitor Trametinib.